Salivary gland carcinoma in children and adolescents: The EXPeRT/PARTNER diagnosis and treatment recommendations.
Aurore SurunDominik T SchneiderAndrea C FerrariTeresa Stachowicz-StencelJelena RasconAnna SynakiewiczAbbas AgaimyKata MartinovaDenis KachanovJelena RoganovicEwa BienGianni BisognoInes B BrechtFrédéric KolbJuliette ThariatAntoine Moya-PlanaDaniel OrbachPublished in: Pediatric blood & cancer (2022)
Salivary gland carcinomas (SGCs) are rare during childhood and adolescence. Consequently, no standardized recommendations for the diagnosis and therapeutic management of pediatric SGC are available, and pediatric oncologists and surgeons generally follow adult guidelines. Complete surgical resection with adequate margins constitutes the cornerstone of treatment. However, the indications and modalities of adjuvant therapy remain controversial and may be challenging in view of the potential long-term toxicities in the pediatric population. This paper presents the consensus recommendations for the diagnosis and treatment of children and adolescents with SGCs, established by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) within the EU-funded PARTNER project (Paediatric Rare Tumours Network - European Registry).